Progression-Free Survival (PFS): Definition, Importance, and Use in Cancer Treatment

Progression-Free Survival (PFS) is a key endpoint used in cancer clinical trials to measure the effectiveness of a treatment. It refers to the length of time during and after treatment that a patient’s cancer does not get worse, or “progress.” PFS is an important marker for evaluating the efficacy of new cancer therapies, particularly when comparing them to standard treatments or placebos.

What is Progression-Free Survival?

In simple terms, PFS is the period during which a patient with cancer experiences no worsening of their disease. The “progression” of cancer refers to the growth of the tumor or the spread of cancer to other parts of the body. PFS is measured from the start of treatment until the cancer begins to grow again or metastasize (spread).

The key elements in defining PFS are:

  • Tumor Progression: A measurable increase in the size of the tumor(s) or the appearance of new tumors, based on radiographic imaging (CT scan, MRI, etc.).
  • Time: The duration from the beginning of treatment until tumor progression is observed.

PFS does not take into account the overall survival of the patient (i.e., how long the patient lives). This makes it distinct from Overall Survival (OS), which is a more definitive, though longer-term, measure of treatment success.

Why is PFS Important?

Progression-Free Survival is an important clinical endpoint because it provides several benefits in the context of cancer research and patient care:

  1. Earlier Indicator of Treatment Efficacy:
    • PFS allows clinicians and researchers to determine more quickly whether a new therapy is effective in preventing cancer progression compared to traditional treatment approaches. This is especially useful in cancers with rapid progression, where waiting for overall survival data might take too long.
  2. Reduces Time to Market for New Treatments:
    • Since measuring overall survival in cancer trials can take years, using PFS as a primary endpoint can shorten the time it takes to determine the effectiveness of a new drug. This is critical for getting new treatments approved and available to patients faster.
  3. Predicts Long-Term Outcomes:
    • A longer PFS is often associated with better overall survival, though this is not always the case. While it doesn’t directly measure survival, a significant increase in PFS suggests that a treatment is helping to control the cancer and may delay the need for further, more aggressive interventions (like chemotherapy or surgery).
  4. Helps Assess Toxicity vs. Benefit:
    • PFS provides a metric to evaluate the benefit of a treatment in relation to its side effects. If a new treatment leads to progression-free survival but comes with serious side effects, the benefit-risk balance can be assessed more effectively.
  5. Can Be Used in Early-Stage Cancer Trials:
    • PFS is often used in phase II clinical trials as an intermediate endpoint to evaluate the potential of a treatment before it progresses to larger phase III trials where overall survival is typically the primary endpoint.

PFS in Different Cancer Types

Progression-Free Survival is relevant across various types of cancer and is used to assess the effectiveness of treatments like chemotherapy, targeted therapies, and immunotherapies. Here are some examples of how PFS is applied in specific cancers:

  1. Lung Cancer:
    • In non-small cell lung cancer (NSCLC), PFS is commonly used to evaluate the efficacy of targeted therapies (e.g., EGFR inhibitors, ALK inhibitors) and immunotherapies (e.g., PD-1 inhibitors, PD-L1 inhibitors).
    • For example, clinical trials of pembrolizumab (Keytruda) in lung cancer often use PFS to assess how long the drug can control tumor growth before cancer progresses.
  2. Breast Cancer:
    • In metastatic breast cancer, PFS is frequently used to evaluate the effectiveness of HER2-targeted therapies (e.g., trastuzumab), as well as new hormonal therapies or chemotherapy regimens.
    • The approval of several newer drugs, such as palbociclib for HER2-positive breast cancer, was based on improvements in PFS.
  3. Ovarian Cancer:
    • In ovarian cancer, treatments such as PARP inhibitors (e.g., olaparib) and chemotherapy often report PFS as a key endpoint. A longer PFS can significantly improve quality of life for patients by delaying the progression to more aggressive disease.
  4. Colorectal Cancer:
    • Trials evaluating biological agents like bevacizumab (Avastin) and cetuximab for colorectal cancer often use PFS as a primary endpoint. A longer PFS can be especially critical in managing metastatic colorectal cancer, where treatment aims to control the disease rather than cure it.
  5. Melanoma:
    • Immunotherapies, such as nivolumab and ipilimumab, have shown significant improvement in PFS for patients with advanced melanoma, demonstrating the efficacy of immune checkpoint inhibitors in prolonging disease control.

How is PFS Measured?

PFS is typically measured through imaging techniques like CT scans, MRI scans, or PET scans, which allow clinicians to monitor tumor size. For PFS to be accurately assessed, imaging studies are typically done at regular intervals (e.g., every 8–12 weeks) to track any changes in tumor size.

  • Response Evaluation Criteria in Solid Tumors (RECIST) is a standardized set of criteria used by oncologists to evaluate tumor progression and response to treatment.
    • Complete Response (CR): No evidence of disease.
    • Partial Response (PR): A significant reduction in the size of the tumor.
    • Stable Disease (SD): No significant change in tumor size.
    • Progressive Disease (PD): An increase in tumor size or the appearance of new tumors.

A patient is considered to have progressed when their tumor reaches the Progressive Disease (PD) category, marking the end of their PFS.

Challenges and Limitations of PFS

While PFS is a valuable endpoint, there are some limitations and challenges:

  1. Not a Guarantee of Overall Survival (OS):
    • While a longer PFS often correlates with longer overall survival, it does not always guarantee that the patient will live longer. Some patients may experience prolonged progression-free intervals but may still face complications or eventual cancer recurrence that reduces their overall survival.
  2. PFS as a Surrogate Endpoint:
    • PFS is often considered a surrogate endpoint, meaning it is an indirect measure of a treatment’s success rather than a direct measure of patient survival. This can sometimes lead to misinterpretations or overstatements of the drug’s effectiveness, particularly if the relationship between PFS and OS is not well-established.
  3. Potential for Bias:
    • In some clinical trials, particularly those with newer therapies, PFS may be influenced by the methods of measuring tumor growth. For instance, certain treatments may shrink tumors but still fail to improve long-term survival, leading to a potential overestimate of treatment benefit based on PFS alone.
  4. Patient-Reported Outcomes (PROs):
    • While PFS focuses on tumor growth, it does not always reflect the symptoms or side effects a patient may experience. In some cases, a treatment may delay tumor progression but cause significant side effects that negatively impact a patient’s quality of life. This is why patient-reported outcomes are also considered when assessing the full impact of a treatment.

Conclusion

Progression-Free Survival (PFS) is an essential metric in cancer clinical trials, helping clinicians and researchers evaluate the efficacy of treatments and guide treatment decisions. Although it is a useful tool in determining how well a treatment controls cancer, it should be considered alongside other factors, including overall survival and quality of life, to give a complete picture of the therapy’s impact. PFS has played a pivotal role in the approval of numerous cancer drugs, particularly in cases where overall survival data may take longer to accumulate, and it continues to be a critical endpoint in oncology research.